At times they covered almost every inch of her body, causing her to choose long sleeves and pants even in the broiling heat of summer so people wouldn't stare.
But that all changed when Anichini, now age 20, began taking the injectable biologic agent Enbrel several years ago after entering the first large study to examine the drug's effectiveness in children and teens with moderate to severe plaque psoriasis. The most common type of psoriasis is plaque psoriasis.
Anichini's lesions started to clear up almost immediately, and these days the Columbia College junior is mostly free of them.
"It really is amazing," she tells WebMD. "I have some flare-ups now and then, especially in the winter. But it is nothing like it was."
Her response to the drug was not unusual.
In the newly reported study in which she took part, 57% of children and teens treated with Enbrel showed a 75% or greater improvement in skin lesions and other symptoms after 12 weeks of treatment, compared with just 11% of kids who got placebo treatments.
Three out of four Enbrel-treated patients showed less dramatic, but still significant, improvements in lesions, compared with one in four placebo-treated patients.
The study appears in the Jan. 17 issue of The New England Journal of Medicine.
"We were surprised at how good the responses were because we used pretty low doses [of Enbrel]," says Northwestern University dermatology and pediatrics professor Amy Paller, MD, who led the study, which was funded by Enbrel makers Amgen and Wyeth Pharmaceuticals.
Enbrel and Psoriasis
Approved by the FDA in the spring of 2004 for the treatment of psoriasis in adults, Enbrel blocks a key chemical messenger in the immune system linked to inflammation known as tumor necrosis factor-alpha (TNF-alpha).
Enbrel has been approved for the treatment of juvenile rheumatoid arthritis, but it had not been studied in children with psoriasis until now, Paller tells WebMD.